HitGen Inc. A
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technolog… Read more
HitGen Inc. A (688222) - Net Assets
Latest net assets as of June 2025: CN¥1.46 Billion CNY
Based on the latest financial reports, HitGen Inc. A (688222) has net assets worth CN¥1.46 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.84 Billion) and total liabilities (CN¥385.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.46 Billion |
| % of Total Assets | 79.08% |
| Annual Growth Rate | 22.68% |
| 5-Year Change | 11.31% |
| 10-Year Change | N/A |
| Growth Volatility | 58.8 |
HitGen Inc. A - Net Assets Trend (2019–2024)
This chart illustrates how HitGen Inc. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for HitGen Inc. A (2019–2024)
The table below shows the annual net assets of HitGen Inc. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.42 Billion | +2.86% |
| 2023-12-31 | CN¥1.38 Billion | +4.20% |
| 2022-12-31 | CN¥1.33 Billion | +0.86% |
| 2021-12-31 | CN¥1.32 Billion | +2.97% |
| 2020-12-31 | CN¥1.28 Billion | +149.71% |
| 2019-12-31 | CN¥511.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to HitGen Inc. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 111.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥201.80 Million | 14.49% |
| Other Components | CN¥1.19 Billion | 85.51% |
| Total Equity | CN¥1.39 Billion | 100.00% |
HitGen Inc. A Competitors by Market Cap
The table below lists competitors of HitGen Inc. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tanco Holdings Bhd
KLSE:2429
|
$724.90 Million |
|
Cpi Property Group SA
XETRA:O5G
|
$725.10 Million |
|
Nexteer Automotive Group Limited
PINK:NTXVF
|
$725.13 Million |
|
Reliance Power Limited
NSE:RPOWER
|
$725.55 Million |
|
Zhongnanhong Culture Group Co Ltd
SHE:002445
|
$724.80 Million |
|
Pactiv Evergreen Inc
NASDAQ:PTVE
|
$724.58 Million |
|
CREDITACCESS GRAMEEN LIMITED
NSE:CREDITACC
|
$724.43 Million |
|
Enghouse Systems Limited
PINK:EGHSF
|
$724.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HitGen Inc. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,358,124,788 to 1,393,046,075, a change of 34,921,287 (2.6%).
- Net income of 51,357,103 contributed positively to equity growth.
- Dividend payments of 31,269,610 reduced retained earnings.
- Other factors increased equity by 14,833,793.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥51.36 Million | +3.69% |
| Dividends Paid | CN¥31.27 Million | -2.24% |
| Other Changes | CN¥14.83 Million | +1.06% |
| Total Change | CN¥- | 2.57% |
Book Value vs Market Value Analysis
This analysis compares HitGen Inc. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 18.13x to 7.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥1.42 | CN¥25.78 | x |
| 2020-12-31 | CN¥3.19 | CN¥25.78 | x |
| 2021-12-31 | CN¥3.28 | CN¥25.78 | x |
| 2022-12-31 | CN¥3.25 | CN¥25.78 | x |
| 2023-12-31 | CN¥3.39 | CN¥25.78 | x |
| 2024-12-31 | CN¥3.48 | CN¥25.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HitGen Inc. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.03%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.26x
- Recent ROE (3.69%) is below the historical average (6.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 23.50% | 45.52% | 0.42x | 1.24x | CN¥69.09 Million |
| 2020 | 5.01% | 26.28% | 0.14x | 1.32x | CN¥-63.77 Million |
| 2021 | 4.82% | 20.38% | 0.18x | 1.30x | CN¥-68.21 Million |
| 2022 | 1.94% | 7.66% | 0.20x | 1.28x | CN¥-104.99 Million |
| 2023 | 3.00% | 10.97% | 0.21x | 1.27x | CN¥-95.09 Million |
| 2024 | 3.69% | 12.03% | 0.24x | 1.26x | CN¥-87.95 Million |
Industry Comparison
This section compares HitGen Inc. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HitGen Inc. A (688222) | CN¥1.46 Billion | 23.50% | 0.26x | $724.85 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |